Denmark· DK-28105364713
Signifor
A pasireotide product containing pasireotide, registered in Denmark by Recordati Rare Diseases. The same ATC class is registered in 15 of our 19 countries.
Checked against Danish Medicines Agency (Denmark) on
Informational only — not a medical device.
Where it is registered
Pasireotide is registered in 15 of 19 countries.
Countries holding a registration under ATC H01CB05 (pasireotide), each read from that country’s own register.
- This record: Denmark, from Danish Medicines Agency (Denmark)
- 10 of them publish a price we can compare per daily dose
Pasireotide · ATC H01CB05
15 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Franceprice
- Icelandprice
- Ireland
- Italyprice
- Netherlands
- Norwayprice
- Polandprice
- Switzerlandprice
- United Kingdom
- United Statesprice
Price per daily dose
What a daily dose of pasireotide costs, country by country.
Normalised to the WHO defined daily dose (1.2 mg), so markets compare like for like.
- 1 market with a comparable price for this class
- Public list prices, converted to USD at the rate date shown
Pasireotide · price per daily dose (1.2 mg)
USD · FX 28 Sept 2026
- CH Switzerland$238.10
The record
At a glance
Danish Medicines Agency (Denmark)- Active substance
- Pasireotide
- Manufacturer
- Recordati Rare Diseases
- Country
- Denmark (DK)
- ATC code
- H01CB05
- ATC class
- Pasireotide
- Defined daily dose
- 1.2 mg, P
- Reimbursed
- Not published by this register
- Source register
- Danish Medicines Agency (Denmark)
- Last checked
- September 30, 2026
Packs & prices · 1
- dk_varenummer28105364713
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
435 interactions on record for pasireotide.
Graded by severity as the source publishes them — 246 severe. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Pasireotide · interactions on record
435 records
- 246 severe
- 184 moderate
- 5 minor
Most severe, free to view
- PapaverineA03AD01severe
- CisaprideA03FA02severe
- OndansetronA04AA01severe
- GranisetronA04AA02severe
- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Same class
Other records under H01CB05
Pasireotide, as other registers publish it.
- FinlandSigniforRecordati Rare Diseases
- DenmarkSigniforRecordati Rare Diseases
- FinlandSigniforRecordati Rare Diseases
- FinlandSigniforRecordati Rare Diseases
- FinlandSigniforRecordati Rare Diseases
- FinlandSigniforRecordati Rare Diseases
- DenmarkSigniforRecordati Rare Diseases
- FinlandSigniforRecordati Rare Diseases
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of Danish Medicines Agency (Denmark). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/b2938640-48a7-4ce5-b992-beaf8862dfd5 GET /v1/drugs/b2938640-48a7-4ce5-b992-beaf8862dfd5?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "pulver og solvens til injektionsvæske, suspension",
"source": "dkma",
"strength": "40 mg",
"auth_role": "MOD",
"dk_drugid": "28105364713",
"substance": "Pasireotide",
"auth_procedure": "Central",
"in_medicinpriser": true,
"registration_date_serial": "41962"
}See everything about pasireotide.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.